Australian patients with metastatic melanoma will be among those helping to determine the optimal duration of treatment with immune checkpoint inhibitors (ICIs). A prospective trial recruiting across multiple sites in Australia and Canada will compare continuous versus intermittent therapy with any approved and publicly funded PD-1 inhibitor. STOP-GAP is just one of a number of ...
Duration of checkpoint inhibitor treatment the next milestone
By Mardi Chapman
12 Mar 2021